Late-onset hypogonadism: Clinical evidence, biological aspects and evolutionary considerations.

ABSTRACT: The growing life expectancy in modern societies has raised scientific interest in identifying medical interventions to alleviate age-associated pathologies such as vascular calcification, cognitive decline, sarcopenia, osteoporosis and sexual dysfunction. Although no such single treatment has thus far been established in humans, some clinicians and patients have set their hopes on testosterone replacement therapy (TRT) as a potential "fountain of youth" for aging men. While TRT has proven effective in ameliorating distinct symptoms of late-onset hypogonadism (LOH), its safety remains to be demonstrated. Besides humans, multiple other species exhibit age-related reductions in circulating testosterone levels, raising the question whether such changes are an inherent, pathological feature of

SUBMITTER: Jaschke N 

PROVIDER: S-EPMC8043243 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature